Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hanna Weissbrot"'
Autor:
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia
Externí odkaz:
https://doaj.org/article/cf0cc2d2d3144e71a74d686f011301aa
Autor:
Alan P Skarbnik, Paul M. Barr, Danielle M. Brander, Hanna Weissbrot, Ian W. Flinn, Peter Sportelli, Suman Kambhampati, Patricia Y. Tsao, Jeffrey Pu, Lindsey E. Roeker, Dana Paskalis, Nicole Lamanna, Stephen J. Schuster, Anthony R. Mato, James A. Reeves, Frederick Lansigan, Bruce D. Cheson, Michael S. Weiss, Nicole LaRatta, Gustavo Fonseca, Hari P. Miskin, Issam Hamadeh, Colleen Dorsey, Andrea Sitlinger, Nilanjan Ghosh, John M. Pagel, Eline T. Luning Prak, Kanti R. Rai, Jakub Svoboda, Jacqueline C. Barrientos
Publikováno v:
Blood. 137:2817-2826
Purpose Intolerance is the most common reason for kinase inhibitor (KI) discontinuation in CLL. Umbralisib a novel, highly selective PI3Kδ/CK1e inhibitor, is active and well tolerated in CLL patients. This phase 2 trial evaluated umbralisib in CLL p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3b7821bd11faf72ff6c583cc332886c
https://doi.org/10.1182/blood.2020007376
https://doi.org/10.1182/blood.2020007376
Autor:
Lindsey E. Roeker, Andrew D. Zelenetz, AnnaLynn M. Williams, Andre Goy, Paul M. Barr, Hande H. Tuncer, Stephen J. Schuster, Joshua Felsenfeld, Brian T. Hill, Alan P Skarbnik, Mansi Malhotra, Colleen Dorsey, Christina Howlett, Allison M. Winter, Ryan Jacobs, Naveed Ali, Nirav N. Shah, Anthony R. Mato, Krista Isaac, Jeffrey J. Pu, Nicole Lamanna, Chaitra S. Ujjani, Melissa Yacur, Arun K Singavi, Eve Tranchito, Peter V. Pickens, Richard R. Furman, Kaitlin Kennard, John N. Allan, Andrea Sitlinger, Sirin Khajavian, Meghan C. Thompson, John M. Pagel, Clive S. Zent, Neil Bailey, Alison R. Sehgal, Danielle M. Brander, Hanna Weissbrot, Chadi Nabhan, Mazyar Shadman, Jakub Svoboda, Frederick Lansigan, Bruce D. Cheson, L. Gashonia, Bhavisha A Patel, Christine A. Garcia, Joanna Rhodes, Timothy F. Burns
Publikováno v:
Haematologica
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b172b0c8dcf6563b824e875a0e38f19
https://doi.org/10.3324/haematol.2018.193615
https://doi.org/10.3324/haematol.2018.193615
Autor:
Nicole Lamanna, Hanna Weissbrot, Mark L. Heaney, Andrew Lipsky, Todd L. Rosenblat, Allison M. Winter, Matthew Chiaramonte, Brian T. Hill, Joseph G. Jurcic
Publikováno v:
Blood. 138:1555-1555
Background: Despite the efficacy of venetoclax (VEN) in frontline CLL, optimal combination regimens and duration of treatment remain unclear. We hypothesized that cytoreduction with bendamustine/rituximab (BR) induction followed by venetoclax/rituxim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cbc26eaa8be5ef37b682732e8147685
https://doi.org/10.1182/blood-2021-150914
https://doi.org/10.1182/blood-2021-150914
Autor:
Neil Bailey, Erica B. Bhavsar, Danielle M. Brander, Ryan Jacobs, Amber C. King, Satyen H. Gohil, Chadi Nabhan, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Pratik Shah, Bruce D. Cheson, Catherine C. Coombs, Hanna Weissbrot, Jacqueline C. Barrientos, John M. Pagel, Michael Y. Choi, Thomas D. Rodgers, Andrea Sitlinger, Rachael Pocock, Nicolas Martinez-Calle, Craig A. Portell, Lindsey E. Roeker, Andrew D. Zelenetz, Allison M. Winter, Colleen Dorsey, Javier Pinilla-Ibarz, Paul M. Barr, Othman S. Akhtar, Kate J Whitaker, Guilherme Fleury Perini, Jason C. Lee, Christine A. Garcia, Jeffrey J. Pu, Pallawi Torka, Timothy J Voorhees, Bita Fakhri, Mazyar Shadman, Ariel F Grajales-Cruz, Toby A. Eyre, Julie Goodfriend, John N. Allan, Joanna Rhodes, Kayla Bigelow, Helen Parry, Nicole Lamanna, Anthony R. Mato, Krista Isaac, Sirin Khajavian, Christopher P. Fox, Stephen J. Schuster, Kentson Lam, Talha Munir, Brian T. Hill, Alan P Skarbnik
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 14
Purpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b4ec23eccb2df4bc0876922b8d9c701
https://pubmed.ncbi.nlm.nih.gov/32366672
https://pubmed.ncbi.nlm.nih.gov/32366672
Autor:
Maryam Sarraf Yazdy, Paul M. Barr, Kaitlin Kennard, Chaitra S. Ujjani, Catherine C. Coombs, John M. Pagel, Arun K Singavi, Erica B. Bhavsar, Hanna Weissbrot, Andre Goy, Toby A. Eyre, Neil Bailey, Hande H. Tuncer, Andrea Sitlinger, Nicole Lamanna, Anthony R. Mato, John N. Allan, Stephen J. Schuster, Chadi Nabhan, Ryan Jacobs, AnnaLynn M. Williams, Christopher P. Fox, Mazyar Shadman, Julie Goodfriend, Joanna Rhodes, Amy A Kirkwood, Brian T. Hill, Alan P Skarbnik, Danielle M. Brander, Anna Schuh, Frederick Lansigan, Lindsey E. Roeker, Andrew D. Zelenetz, Nirav N. Shah, Bruce D. Cheson, Colleen Dorsey, Sivraj Muralikrishnan, Allison M. Winter
Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdcba9b71b36981f8316df520fd92b48
https://europepmc.org/articles/PMC6538868/
https://europepmc.org/articles/PMC6538868/
Autor:
Michael S. Weiss, Ian W. Flinn, Anthony R. Mato, James A. Reeves, Nicole Lamanna, E. Luning Prak, Colleen Dorsey, Stephen J. Schuster, N.M. LaRatta, Frederick Lansigan, John M. Pagel, Gustavo Fonseca, Hari P. Miskin, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Hanna Weissbrot, Jakub Svoboda, Patricia Y. Tsao, Peter Sportelli, Jeffrey J. Pu, Alan P Skarbnik, Andrea Sitlinger, Dana Paskalis, Danielle M. Brander, Jaqueline C. Barrientos
Publikováno v:
Hematological Oncology. 37:88-89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::febcba62422904b919361c94f2003ecc
https://doi.org/10.1002/hon.56_2629
https://doi.org/10.1002/hon.56_2629
Autor:
Amber C. King, Michael Y. Choi, Guilherme Fleury Perini, Sirin Khajavian, Mazyar Shadman, Kentson Lam, Jason C. Lee, Bita Fakhri, Jeffrey J. Pu, Danielle M. Brander, Pratik Shah, Colleen Dorsey, Bruce D. Cheson, Kayla Bigelow, Talha Munir, Neil Bailey, Ryan Jacobs, Stephen J. Schuster, Thomas D. Rodgers, Hanna Weissbrot, Satyen H. Gohil, Lindsey E. Roeker, Andrew D. Zelenetz, Andrea Sitlinger, Pallawi Torka, Kate J Whitaker, Chaitra S. Ujjani, Nicolas Martinez-Calle, Christopher P. Fox, Brian T. Hill, Alan P Skarbnik, Paul M. Barr, Chadi Nabhan, Javier Pinilla Ibarz, Anthony R. Mato, Krista Isaac, Christine A. Garcia, Ariel F Grajales-Cruz, Allison M. Winter, Maryam Sarraf Yazdy, Toby A. Eyre, John M. Pagel, Jacqueline C. Barrientos, John N. Allan, Erica B. Bhavsar, Othman S. Akhtar, Julie Goodfriend, Helen Parry, Nicole Lamanna, Craig A. Portell, Timothy J Voorhees, Catherine C. Coombs, Rachael Pocock, Joanna Rhodes
Publikováno v:
Blood. 134:502-502
Introduction: Venetoclax (VEN) based therapy has become a standard of care in front line and relapsed-refractory (R/R) CLL based on favorable efficacy and toxicity. Whereas prospective data regarding activity of therapies following ibrutinib (IBR) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::931e807f711f64fe625d8835d32c0fa4
https://doi.org/10.1182/blood-2019-123747
https://doi.org/10.1182/blood-2019-123747
Autor:
Anthony R. Mato, Bruce D. Cheson, Krish Patel, Alan P Skarbnik, Maryam Sarraf Yazdy, Hanna Weissbrot, Lori A. Leslie, Lindsey E. Roeker, Mazyar Shadman, Charlene C. Kabel, Ryan Jacobs, Andre Goy, John M. Pagel, Isaac Deonarine, Nicole Lamanna, Sarah E. Stump, Neil Bailey, Tatyana Feldman, Sirin Khajavian, Jessica Weiss, Umair Jarral, Julie Goodfriend, Chaitra S. Ujjani, Kate J Whitaker, Catherine C. Coombs, Benyam Muluneh
Publikováno v:
Blood. 134:4311-4311
Introduction: Acalabrutinib (acala) is an irreversible, second generation Bruton tyrosine kinase inhibitor (BTKi) approved by the FDA for the treatment of relapsed/refractory (R/R) mantle cell lymphoma, and is in advanced stages of clinical testing f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cbdfaf68222e7aad72bee67caa233ef
https://doi.org/10.1182/blood-2019-130062
https://doi.org/10.1182/blood-2019-130062
Autor:
Allison M. Winter, Hande H. Tuncer, Maryam Sarraf Yazdy, Frederick Lansigan, Anna Schuh, Toby A. Eyre, John N. Allan, Nicole Lamanna, Anthony R. Mato, John M. Pagel, Lindsey E. Roeker, Stephen J. Schuster, Andre Goy, Paul M. Barr, Andrea Sitlinger, AnnaLynn M. Williams, Hanna Weissbrot, Bruce D. Cheson, Mazyar Shadman, Arun K Singavi, Nirav N. Shah, Chaitra S. Ujjani, Erica B. Bhavsar, Kaitlin Kennard, Christopher P. Fox, Ryan Jacobs, Brian T. Hill, Alan P Skarbnik, Amy A Kirkwood, Catherine C. Coombs, Joanna Rhodes, Neil Bailey, Chadi Nabhan, Sivraj Muralikrishnan, Danielle M. Brander
Publikováno v:
Blood. 132:3142-3142
Introduction: Venetoclax (Ven) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (Ven mono) or in combination (Ven paired) with rituximab based on clinical trials with selected patients (pts) and limited ibru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd113a53e5129b7cee571faf95ba136b
https://doi.org/10.1182/blood-2018-99-114840
https://doi.org/10.1182/blood-2018-99-114840